Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meloxicam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | GLA | P06280 | 1/20 | 0.98 |
| ▸ | EDNRA | P25101 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | PKM | P14618 | 2/20 | 0.76 |
| ▸ | THPO | P40225 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meloxicam SCHEMBL3576 | 0.99 | PTGS1 (1.00) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL3752395 | 0.99 | PTGS1 (1.00) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL23589638 | 0.99 | PTGS1 (1.00) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL20168549 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL332206 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL3373822 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL20168506 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL20165003 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL332632 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL7898655 | 0.98 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140332438-A1 | WATER-SOLUBLE MELOXICAM GRANULES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-11-13 | — | — | US | claimed |
| US-20130193028-A1 | WATER-SOLUBLE MELOXICAM GRANULES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| CN-114796133-A | Pharmaceutical preparation for injection and preparation method thereof | 浙江仙琚萃泽医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-8008480-B2 | Process for the purification of meloxicam | NORBROOK LABORATORIES LTD (IE) | 2011-08-30 | — | — | US | disclosed |
| US-20090163707-A1 | Process for the Purification of Meloxicam | MCELROY LIAM | 2009-06-25 | — | — | US | disclosed |
| EP-1923392-B1 | Process for the purification of meloxicam | NORBROOK LAB LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008062151-A1 | PROCESS FOR THE PURIFICATION OF MELOXICAM | NORBROOK LABORATORIES LTD (GB) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119647-A1 | Process for the Purification of Meloxicam | ULSTER BANK LIMITED (IE) | 2008-05-22 | — | — | US | disclosed |
| EP-1923392-A1 | Process for the purification of meloxicam | NORBROOK LABORATORIES LIMITED (GB) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163707-A1 | Process for the Purification of Meloxicam | MB, MYADM, MGAM | PTGS2 77/4885PTGS1 64/4885ABCB11 2170/4885 |
| US-20080119647-A1 | Process for the Purification of Meloxicam | MB, MYADM, MGAM | PTGS2 77/4885PTGS1 64/4885ABCB11 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.